-
1
-
-
68949206506
-
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron
-
doi: 10.1007/s00520-008-0572-4
-
Adams LM, Johnson B, Zhang K, Yue L, Kirby L, Lebowitz P, and Stoltz R (2009) Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Support Care Cancer doi: 10.1007/s00520-008-0572-4.
-
(2009)
Support Care Cancer
-
-
Adams, L.M.1
Johnson, B.2
Zhang, K.3
Yue, L.4
Kirby, L.5
Lebowitz, P.6
Stoltz, R.7
-
2
-
-
33846872438
-
Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)
-
Arpornwirat W, Albert I, Hansen VL, Russo MA, Ross GA, Pence CD, Bandekar RR, and Grunberg SM (2006) Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 24 (Suppl 18):8512.
-
(2006)
J Clin Oncol
, vol.24
, Issue.SUPPL. 18
, pp. 8512
-
-
Arpornwirat, W.1
Albert, I.2
Hansen, V.L.3
Russo, M.A.4
Ross, G.A.5
Pence, C.D.6
Bandekar, R.R.7
Grunberg, S.M.8
-
3
-
-
67650851656
-
Phase III results for the novel Neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day i.v./oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)
-
Aziz Z, Arpornwirat W, Herrstedt J, Camlett I, Piontek T, Ranganathan S, Schnyder J, Bandekar RR, Levin J, and Shaharyar A (2008) Phase III results for the novel Neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day i.v./oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 26 (Suppl 15):20512.
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL. 15
, pp. 20512
-
-
Aziz, Z.1
Arpornwirat, W.2
Herrstedt, J.3
Camlett, I.4
Piontek, T.5
Ranganathan, S.6
Schnyder, J.7
Bandekar, R.R.8
Levin, J.9
Shaharyar, A.10
-
4
-
-
24944531981
-
Measurement of radioactivity in biological experiments
-
Garrett ER and Hirtz JL eds Dekker, New York
-
Botta L, Gerber H-U, and Schmid K (1985) Measurement of radioactivity in biological experiments, in Drug Fate and Metabolism, Methods and Techniques (Garrett ER and Hirtz JL eds) vol 5, pp 99-134, Dekker, New York.
-
(1985)
Drug Fate and Metabolism, Methods and Techniques
, vol.5
, pp. 99-134
-
-
Botta, L.1
Gerber, H.-U.2
Schmid, K.3
-
5
-
-
33750102850
-
A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: Validation and applications
-
Bruin GJ, Waldmeier F, Boernsen KO, Pfaar U, Gross G, and Zollinger M (2006) A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: validation and applications. J Chromatogr A 1133:184-194.
-
(2006)
J Chromatogr A
, vol.1133
, pp. 184-194
-
-
Bruin, G.J.1
Waldmeier, F.2
Boernsen, K.O.3
Pfaar, U.4
Gross, G.5
Zollinger, M.6
-
6
-
-
67650854766
-
Casopitant for preventing postoperative vomiting in patients receiving opioids: Pooled data analysis
-
Chung F, Singla N, Singla S, Grenier A, and Russo M (2006) Casopitant for preventing postoperative vomiting in patients receiving opioids: pooled data analysis. Anaesthesiology 105:A206.
-
(2006)
Anaesthesiology
, vol.105
-
-
Chung, F.1
Singla, N.2
Singla, S.3
Grenier, A.4
Russo, M.5
-
7
-
-
0027275566
-
Physiological parameters in laboratory animals and humans
-
Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharmacol Res 10:1093-1095.
-
(1993)
Pharmacol Res
, vol.10
, pp. 1093-1095
-
-
Davies, B.1
Morris, T.2
-
8
-
-
79953077671
-
Phase III results of a novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)
-
Grunberg SM, Aziz Z, Shaharyar A, Herrstedt J, Roila F, VanBelle S, Bandekar RR, Russo M, and Arpornwirat W (2008) Phase III results of a novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 26 (Suppl 15):9540.
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL. 15
, pp. 9540
-
-
Grunberg, S.M.1
Aziz, Z.2
Shaharyar, A.3
Herrstedt, J.4
Roila, F.5
VanBelle, S.6
Bandekar, R.R.7
Russo, M.8
Arpornwirat, W.9
-
9
-
-
67650793699
-
Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
-
Herrstedt J, Grunberg S, Rolski J, Bandekar RR, Guckert ME, Camlett I, Russo MW, Aziz Z, and Thorn S (2008) Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 26 (Suppl 15):9549.
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL. 15
, pp. 9549
-
-
Herrstedt, J.1
Grunberg, S.2
Rolski, J.3
Bandekar, R.R.4
Guckert, M.E.5
Camlett, I.6
Russo, M.W.7
Aziz, Z.8
Thorn, S.9
-
10
-
-
68949208670
-
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
-
doi: 10.1007/s00520-008-0571-5
-
Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, and Blum R (2009) Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer doi: 10.1007/s00520-008-0571-5.
-
(2009)
Support Care Cancer
-
-
Johnson, B.1
Adams, L.2
Lu, E.3
Zhang, K.4
Lebowitz, P.5
Lates, C.6
Blum, R.7
-
11
-
-
50049134889
-
Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret
-
Minthorn E, Mencken T, King AG, Shu A, Rominger D, Gontarek RR, Han C, Bambal R, and Davis CB (2008) Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret. Drug Metab Dispos 36:1846-1852.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 1846-1852
-
-
Minthorn, E.1
Mencken, T.2
King, A.G.3
Shu, A.4
Rominger, D.5
Gontarek, R.R.6
Han, C.7
Bambal, R.8
Davis, C.B.9
-
12
-
-
0029717657
-
High sensitivity collisional-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer
-
Morris HR, Paxton T, Dell A, Langhorne J, Berg M, Bordoli RS, Hoyes J, and Bateman RH (1996) High sensitivity collisional-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer. Rapid Commun Mass Spectrom 10:889-896.
-
(1996)
Rapid Commun Mass Spectrom
, vol.10
, pp. 889-896
-
-
Morris, H.R.1
Paxton, T.2
Dell, A.3
Langhorne, J.4
Berg, M.5
Bordoli, R.S.6
Hoyes, J.7
Bateman, R.H.8
-
13
-
-
46749132406
-
Casopitant, a neurokinin-1 receptor antagonist with antiemetic and antinausea activity
-
Navari RM (2008) Casopitant, a neurokinin-1 receptor antagonist with antiemetic and antinausea activity. Curr Opin Investig Drugs 9:774-785.
-
(2008)
Curr Opin Investig Drugs
, vol.9
, pp. 774-785
-
-
Navari, R.M.1
-
14
-
-
0033832991
-
Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics
-
Oliveira EJ and Watson DG (2000) Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed Chromatogr 14:351-372.
-
(2000)
Biomed Chromatogr
, vol.14
, pp. 351-372
-
-
Oliveira, E.J.1
Watson, D.G.2
-
15
-
-
0032952578
-
The use of preparative high performance liquid chromatography with tandem mass spectrometric directed fraction collection for the isolation and characterization of drug metabolites in urine by nuclear magnetic resonance spectroscopy and liquid chromatography/sequential mass spectrometry
-
Plumb RS, Ayrton J, Dear GJ, Sweatman BC, and Ismail IM (1999) The use of preparative high performance liquid chromatography with tandem mass spectrometric directed fraction collection for the isolation and characterization of drug metabolites in urine by nuclear magnetic resonance spectroscopy and liquid chromatography/sequential mass spectrometry. Rapid Commun Mass Spectrom 13:845-854.
-
(1999)
Rapid Commun Mass Spectrom
, vol.13
, pp. 845-854
-
-
Plumb, R.S.1
Ayrton, J.2
Dear, G.J.3
Sweatman, B.C.4
Ismail, I.M.5
-
16
-
-
33847081694
-
What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs
-
Roffey SJ, Obach RS, Gedge JI, and Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17-43.
-
(2007)
Drug Metab Rev
, vol.39
, pp. 17-43
-
-
Roffey, S.J.1
Obach, R.S.2
Gedge, J.I.3
Smith, D.A.4
-
17
-
-
33747393831
-
Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC)
-
Rolski J, Ramlau R, Dediu M, Russo MW, Ross GA, Mather RA, Bandekar RR, and Grunberg SM (2006) Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 24 (Suppl 18):8513.
-
(2006)
J Clin Oncol
, vol.24
, Issue.SUPPL. 18
, pp. 8513
-
-
Rolski, J.1
Ramlau, R.2
Dediu, M.3
Russo, M.W.4
Ross, G.A.5
Mather, R.A.6
Bandekar, R.R.7
Grunberg, S.M.8
-
18
-
-
67650787385
-
Efficacy of oral casopitant mesylate, a novel neurokinin-1 receptor antagonist, with intravenous ondansetron HCl in the prevention of postoperative nausea and vomiting (PONV) in high-risk patients
-
Singla N, Chung F, Singla S, Grenier A, Kutsogiannis D, Kett A, Pergolizzi J, and Russo M (2006) Efficacy of oral casopitant mesylate, a novel neurokinin-1 receptor antagonist, with intravenous ondansetron HCl in the prevention of postoperative nausea and vomiting (PONV) in high-risk patients. Eur J Anaesthesiol 23 (Suppl 37):A614.
-
(2006)
Eur J Anaesthesiol
, vol.23
, Issue.SUPPL. 37
-
-
Singla, N.1
Chung, F.2
Singla, S.3
Grenier, A.4
Kutsogiannis, D.5
Kett, A.6
Pergolizzi, J.7
Russo, M.8
-
19
-
-
67650854765
-
Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day i.v./oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
-
Strausz J, Rolski J, Aziz Z, Guckert ME, Wright O, Bandekar RR, Thorn S, and Wissel P (2008) Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day i.v./oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 26 (Suppl 15):20585.
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL. 15
, pp. 20585
-
-
Strausz, J.1
Rolski, J.2
Aziz, Z.3
Guckert, M.E.4
Wright, O.5
Bandekar, R.R.6
Thorn, S.7
Wissel, P.8
|